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Abstract  
Background As a way to determine markers of infection or disease informing disease management, and to reveal disease-associated immune 
mechanisms, this study sought to measure antibody and T cell responses against key lung pathogens and to relate these to patients’ microbial 
colonization status, exacerbation history and lung function, in Bronchiectasis (BR) and Chronic Obstructive Pulmonary Disease (COPD).   
Methods 119 patients with stable BR, 58 with COPD and 28 healthy volunteers were recruited and spirometry was performed. Bacterial 
lysates were used to measure specific antibody responses by ELISA and T cells by ELIspot. Cytokine secretion by lysate-stimulated T cells was 
measured by multiplex cytokine assay whilst activation phenotype was measured by flow cytometry.  
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Results Typical colonization profiles were observed in BR and COPD, dominated by P.aeruginosa, H.influenzae, S.pneumoniae and 
M.catarrhalis. Colonization frequency was greater in BR, showing association with increased antibody responses against P.aeruginosa 
compared to COPD and HV, and with sensitivity of 73% and specificity of 95%. Interferon-gamma T cell responses against P.aeruginosa and 
S.pneumoniae were reduced in BR and COPD, whilst reactive T cells in BR had similar markers of homing and senescence compared to healthy 
volunteers. Exacerbation frequency in BR was associated with increased antibodies against P. aeruginosa, M.catarrhalis and S.maltophilia. 
T cell responses against H.influenzae showed positive correlation with FEV1% (r=0.201, p=0.033) and negative correlation with Bronchiectasis 
Severity Index (r=-0.287, p=0.0035).   
Conclusion Our findings suggest a difference in antibody and T cell immunity in BR, with antibody being a marker of exposure and disease 
in BR for P.aeruginosa, M.catarrhalis and H.influenzae, and T cells a marker of reduced disease for H.influenzae.   
    
Introduction  
The chronic lung diseases of bronchiectasis (BR) and chronic obstructive pulmonary disease (COPD) are both associated with recurrent airway 
infections.  COPD is a major cause of death globally, with numbers of deaths rising (1), and BR is underestimated with incidence rising in the 
UK by around 6% annually (2). Whilst they differ in disease causation, established disease in both is mainly characterised by repeated or 
persistent heavy bacterial colonization of the damaged lower respiratory tract. Such infection is associated with inflammation, mucus 
production, and reduced ciliary action, which promotes further infection, inflammation and tissue damage, in a vicious cycle (3). Studies 
have suggested that infection causes disease exacerbation and diminished lung function, which are often proportional to the bacterial load 
and to reduced diversity (4,5). More recent findings propose more species-rich lung ecologies where alterations in specific bacterial 
populations, dysbiosis, is at the heart of clinical disease (6,7). Pathogenic bacteria, as determined clinically by microbiological culture of 
expectorated sputum, are dominated by organisms specific to these diseases including Pseudomonas aeruginosa, Haemophilus influenzae, 
Streptococcus pneumoniae and Moraxella catarrhalis (8). Recent studies using DNA-sequencing technology reveal more detailed bacterial 
ecosystems in the lungs of diseased patients, but with culture approaches mainly corroborated (9,10). P.aeruginosa is considered the major 
cause of morbidity (increased exacerbations and reduced lung function) and mortality in BR (11), particularly during chronic infection and 
mucoid characteristics of the bacterium (12), which may allow evasion of host immunity. Non-typeable strains of Haemophilus influenzae 
(NTHi) are frequently found in BR (13) and are not targeted by current vaccines. Both pathogens are also common in COPD albeit with a 
reduced frequency of Pseudomonas infections as compared to BR (14). Furthermore, less frequent suppurative infection and sputum 
production in COPD results in lower detection of pathogenic microbes, implying fewer infections than BR. Failure to produce sputum for 
microbiology, particularly in younger BR patients and in many COPD patients, as well intermittent negative cultures, means that immune 
biomarkers of disease may provide a useful adjunct for directing clinical management.  
Knowledge of immunity in BR is limited, but studies suggest immune system genes that are involved in presentation of antigens to CD4+ T 
cells, such as HLA-DR1 and DQ5, play a role (15,16). Notably, a role for adaptive immune responses (specific antibodies and T cells) in 
protection against P.aeruginosa and H.influenzae, has been demonstrated in human vaccine trials in cystic fibrosis-related bronchiectasis 
(17,18) and in mouse vaccination models (19,20). Furthermore, the abovementioned lung pathogens appear in individuals with defined 
immunodeficiencies (21), underlining the role of antibodies and phagocytes in protection. Whilst healthy individuals are exposed to the 
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same pathogenic organisms as diseased individuals, healthy lungs typically have low levels of bacterial species, reflecting the naso-pharynx 
(22). Immune responses against pathogenic microbes do not cause overt immunopathology in healthy individuals, but may contribute to 
disease in colonized patients due to continuous immune stimulation by the localised high antigen doses, particularly through excessive Th17 
responses that promote neutrophil infiltration (23). Together with inflammatory cytokines, neutrophils are abundant in the sputum of BR 
patients, and decline after antibiotic treatment (24).  It is possible that dysfunction of both innate and adaptive immunity contribute directly 
or indirectly to disease in both BR and COPD. The aim of this study was to characterise antibody and T cell responses against key lung 
microbes in disease-stable patients with BR and COPD, characterised by the Bronchiectasis Severity Index (BSI) and GOLD guidelines, 
respectively, in comparison to controls (healthy volunteers), and to relate the immune responses to culture-based bacterial colonization, 
lung function and frequency of exacerbation.    
  
Methods  
Study participants and samples  
Ethical approval for the project was granted by the local NHS Research Ethics Committee, the NRES Committee North East – County Durham 
& Tees Valley (ref 12/NE/0248). Adult patients with (nonCF) BR, COPD and healthy volunteer (HV) controls, were recruited at the Freeman 
Hospital, Newcastle upon Tyne. Female to male ratio was about 1.5:1. BR is routinely confirmed by high-resolution computed tomography 
(HCRT), and COPD according to prevailing GOLD guidelines (BTS and NICE 2010, 25).  Diverse aetiologies of BR were included in the study, 
with the exception of known immunodeficiency.  
Patients were clinically stable at the time of assessment. They underwent spirometry to determine forced expiratory volume in 1 second 
(FEV1), and Forced Vital Capacity (FVC), from which FEV1 % predicted, FEV1/FVC ratio and FVC % predicted were obtained. The bronchiectasis 
severity index (BSI) score, as previously validated (26), was assessed. Patients were divided into 2 groups: either those with one severe 
exacerbation requiring hospitalisation or those with 3 or more exacerbations per year, compared to those not requiring hospitalisation and 
having less than 3 exacerbations per year. The exacerbations were determined for the preceding 12 months. Colonization history of patients 
was also available going back at least 4 years.  Patients were categorised by pathogen status based on positive sputum cultures. ‘Chronic 
colonization’ was defined here as 2 positive sputum cultures at least 3 months apart in 12 months.  ‘Chronic currently’ was defined as a 
positive sputum culture at time of blood sampling (for immune responses), and more than 2 positive sputum cultures in 12 months. 
‘Previously chronic’ was defined as more than 2 positive sputum cultures in 12 months >2 years ago. ‘Occasional’ infection was >1 positive 
sputum culture per year. ‘No colonization’ was sputum culture negative over at last 3 years (Table 3).  
Sample processing and Bacterial Culture  
Heparinized venous blood samples from patients and healthy controls and were processed to give plasma for ELISA and peripheral blood 
mononuclear cells (PBMC) for T cell assays (detailed in supplement). Sputum samples were cultured in the Microbiology Department, 
Freeman Hospital, according to national standards.   
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Enzyme-Linked Immunosorbent Assay (ELISA) for serum antibody measurement   
An indirect enzyme-linked immunosorbent assay (ELISA) method was used: to determine optimal dilutions for the coating of microbe-derived 
antigens, for initial serum screening, and to undertake titration for total IgG (all subclasses combined) to give an end-point titre (e.g. 1 in 
1000), and for the measurement of individual Ig subclasses (given as absorbance for 1 in 25 dilution), as described previously (27)(see 
supplement).   
T cell responses to microbial antigens  
ELIspot as previously optimised and described (28) (see supplement) was used to measure T cell responses against a range of stimuli including 
bacterial lysates plus selected peptide epitopes where available. For cell activation and surface staining of cells, PBMC were thawed and 
activated with stimuli for 20 hours as detailed in the supplement. Intracellular staining was performed to determine the number and 
phenotype of IFNγ-producing or activated CD69+ T cells following stimulation.  
Measurement of cytokines in culture supernatants using multiplex ELISA  
Cytokines in supernatants from stimulated PBMCs were measured using the Mesoscale Scale Discovery (MSD) multiplex cytokine Kit (Meso 
Scale Diagnostic, LLC, Gaithersburg, USA). Multiplex kit – pro-inflammatory panel 1 (for IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNFα) and 
cytokine panel 2 (IL-17A, IL-5) were used. See supplement.  
Statistics  
The immunological data was tested for normal distribution using the Shapiro-Wilk test. For normally distributed data t-test and Pearson 
correlation was used whilst for not normally distributed data the Mann-Whitney U test and Spearman’s correlation was used. A priori 
calculations based on our previous data suggested that sufficient numbers were included to detect a modest effect with 0.9 power to a 
significance level of 0.05. SPSS v.15 and Graph Pad Prism were used for analysis. The cut-off value for statistical significance was p<0.05.  
  
Results  
Clinical data  
This study examined antigen-specific immune responses in 119 BR and 58 COPD patients, and in 28 HV (Table 1), against lung pathogens that 
are commonly isolated from these patient groups. The patient groups showed typical clinical features, similar to previously-published reports 
e.g. average FEV1 % predicted, which was 68 for BR, 49 for COPD and 113 for HV. FVC % predicted and FEV1/FVC ratio were also reduced in 
the patient groups compared to HV. The BR group was predominantly of a post-infection aetiology, whilst COPD was smoking-related, and 
all patients with BR and COPD were in a clinically stable state with no current exacerbation. At the time of taking the blood samples, the BR 
group had a higher proportion of patients producing sputum (93%) that could be microbiologically tested than COPD (66%), and BR patients 
showed greater overall populations infected with the main bacterial species (Table 2), many with multiple species. H.influenzae was the 
most commonly identified species in both BR and COPD, followed by P.aeruginosa, S.pneumoniae and M.catarrhalis in BR, and M.catarrhalis, 
S.pneumoniae and P.aeruginosa in COPD.   
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Antibody responses   
The first experiments involved ELISA to determine antibody levels (total specific IgG), by end-point titre, against the main bacterial species 
in BR, COPD and HV. BR showed significantly higher levels of antibody against P.aeruginosa, H.influenzae and S.maltophilia compared to HV 
(Fig.1a). COPD failed to show significant increase from HV for any of the bacteria. HV only showed significantly higher antibody responses 
than BR and COPD against S.pneumoniae.   
The next aim was to relate specific IgG antibody levels against bacteria, to bacterial colonization status and history.  Because of the relatively 
low infection rates in COPD, the numbers were insufficient to determine significance, and so we focussed on BR. BR patient pathogen status 
was analysed and condensed into a categorization shown in Table 3, indicating ‘current chronic’, ‘previous chronic’, ‘occasional’, or ‘no 
colonization’. Whilst there was an overall trend for antibody titre to increase based on colonization (Fig.1b), this was only significant for 
P.aeruginosa and S.maltophilia. We further studied immunoglobulins by class and isotype across the disease groups and found in general 
higher levels of IgG1 and IgA in BR than COPD (Fig.1f-g).   
T cell responses  
T cell responses, in the form of IFNγ spot-forming cells per 106 PBMC, were measured against the bacterial antigens as for the antibodies. In 
contrast to the antibody responses, there was an overall trend towards the BR and COPD groups having lower T cell responses than the HV 
group (Fig.1c). BR and COPD both had significantly lower responses than HV against P.aeruginosa and S.pneumoniae. As with the antibody 
responses, the relatively low infection rates in COPD meant that there were insufficient numbers of infected patients to determine 
significance and so BR was focussed upon for relating to colonization (Fig.1d). Whilst there was an overall trend for T cell responses against 
all antigens to associate with an occasional number of exposures, as opposed to none or chronic, this was not significant.   
Exacerbation and Lung Function  
The contribution of bacterial colonisation, as per Table 3, to lung function as measured by FEV1% predicted, was examined in the BR cohort. 
Overall there was a downward trend in lung function as bacterial colonisation became more frequent and with current positive cultures 
(Fig.2a), with P.aeruginosa, M.catarrhalis and S.maltophilia all showing a significant reduction. The numbers with M.catarrhalis and 
S.maltophilia were low (n=10 and 9, respectively) with 52% and 75% of these, respectively, being co-colonised with P.aeruginosa.   
Since exacerbation of disease is a key event in need of urgent clinical management, and makes up part of the validated BSI scoring, 
exacerbation history of the BR patients was used to determine whether there were any informative associations with immunological 
responses. The patients were compared based on them having less than 3 exacerbations, greater than or equal to 3, and those that were 
hospitalised within the last year. This breakdown of the patients was first validated by examining the FEV1% predicted within the groups 
compared to HV (Fig.2b). A significant decrease in lung function was seen moving from HV, through <3 exacerbations, >3 exacerbations, to 
hospitalised. Since the hospitalised group comprise a variable causality (and not necessarily greater disease) and was relatively small in 
number, this was omitted from further analysis. Small but statistically significant increases in IgG titres against P.aeruginosa, H.influenzae 
and M.catarrhalis were seen between <3 and >3 exacerbations (Fig.3a-c). For T cell responses no significant differences were seen between 
the 2 groups for any antigen (Fig.3d-f).   
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T cell phenotypes  
Since T cell responses of a single Th type (Th1/IFNγ) may not be the only response against the lung bacteria, antigen-specific T cell cytokine 
responses were also measured in the supernatants of antigen-stimulated PBMC by multiplex cytokine analysis (Fig.4a-h). A sub-group of BR 
patients who were good responders to the antigens, determined by both IFNγ ELIspot and by CD69 expression following antigen-stimulation, 
were selected for stimulation, as well as similarly good HV responders. For IFNγ, IL-2 and IL-17 responses the BR patients showed a trend, 
though not significant, towards reduced levels for both P.aeruginosa  and H.influenzae compared to HV. For IL4, BR patients showed 
marginally reduced responses for P.aeruginosa but significantly increased responses to H.influenzae compared to HV, although the 
responses showed considerable variability. Finally, IL-10 responses showed a trend for increased response in BR over HV for both antigens, 
but again with much variability. All other cytokine responses tested were equivocal.  
Flow cytometry analysis was used to further characterise antigen-responding T cells in the same subgroups of BR and HV. Similar proportions 
of activated CD69+ CD4+ T cells were seen in BR and HV following stimulation with P.aeruginosa and H.influenzae, all being significantly 
higher than the unstimulated (medium) control (Fig.5e). Co-staining of the activated CD4+ T cells with CD69 and for IFNγ intracellularly 
showed a concordance of the two forms of activation but showed that there were more CD69+ cells than IFNγ+ cells (supplement). Staining 
of the CD69+ stimulated cells for other potentially important markers (see supplement Fig.S1), showed significant levels of staining (above 
isotype controls) on CD4+ CD69+ T cells (Fig.5e-i), but no significant difference between BR patient and HV cells.   
When the relationship between T cell responses (IFNγ ELIspot) and lung function (FEV1% predicted) was examined, a significant positive 
correlation (Fig.6a), albeit weak (r=0.201; p=0.033), was found only with T cell response against H.influenzae. With removal of the outlier, 
significance was still retained (r=0.186, p=0.049). Furthermore, a stronger (negative) correlation was observed between BSI and anti-
H.influenzae T cell responses (Fig.6c)(r=-0.287; p=0.003), and again significance remained upon removal of an outlier (r=-0.265, p=0.0035). 
Conversely, a moderate negative correlation was seen (Fig.6b) with antibodies against H.influenzae (r=-0.224; p=0.018), but none with BSI 
(Fig.6d).  This suggests that T cell responses are associated with improved lung function and less severe disease, whereas higher levels of H. 
influenzae antibodies are associated with poorer lung function. Overall, no relationships were evident between the magnitudes of antibody 
and T cell responses against any of the bacteria examined. Furthermore, T cell and antibody responses against bacteria showed no 
relationships with one another (data not shown).   
Discussion  
This study began by comparing immune responses against common lung pathogens in BR, COPD and HV. The clinical categorisation of the 
patients followed standard processes and was in keeping with other studies in the field, as were the microbiology results obtained.  One 
expectation was that the degree of exposure to the microbes will be proportional to the magnitude of immune response measured. This 
was broadly the case for antibody responses, which were higher in BR than COPD and HV, particularly against P.aeruginosa, H.influenzae 
and S.maltophilia, reflecting rates of positive sputum cultures in BR and COPD. Measurement of isotype components of the antibody 
responses against P.aeruginosa showed a high IgG1 component in BR and HV, compared to COPD which had a higher IgM. This may suggest 
that COPD has reduced isotype switching, which is usually controlled by cognate T cell responses, through CD40:CD40L interaction and 
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through cytokines. Reduced or altered antibody responses as we have seen here could be due to increased regulatory T cells, as have been 
demonstrated in COPD, which may depress protective immunity (36).   
Having found specific antibody responses to be increased in BR, the question was whether these responses showed a direct dynamic 
relationship with colonization levels. Sufficient numbers for this analysis were only available in the BR group. Whilst there was a trend for 
increasing antibodies with colonisation for each individual pathogen, only P.aeurginosa and S.maltophilia showed significance. We 
categorised patients based on their exacerbation frequency (<3, >3) which were validated by showing reducing lung function. Although 
significant, only modest increases in antibody against  
P.aeruginosa, M.catarrhalis and H.influenzae were found in BR with >3 exacerbations compared to <3. Antibody response only against 
H.influenzae showed a negative correlation with FEV1% predicted, suggesting it to be a marker of disease and exposure.  
The measurement of T cell responses against lung pathogens may be useful for the diagnosis of latent infection, as is the case of the 
Quantiferon test for Mycobacterium tuberculosis (Mtb). In this study T cell responses showed an overall tendency for reduction in BR and 
COPD compared to HV, associated with colonisation status, with responses to P.aeruginosa and S.pneumoniae being significantly reduced. 
This suggests that increased infection and exposure may exhaust the T cell response. Within the BR group T cell responses showed a trend 
for being highest in the group that had occasional infections, for all pathogens tested. The highest T cell responses were found for  
H.influenzae and M.catarrhalis which coincides with them having intracellular phases that require T cells for efficient immune protection or 
eradication. T cell responses did not show any associations with exacerbation level. However, increased IFNγ ELIspot T cell responses against 
H.influenzae showed significant positive association, albeit weak, with lung function (FEV1%) and negative association with BSI, which may 
suggest that T cells are protective against disease, in contrast to antibody responses which showed a negative correlation with FEV1%, and 
may simply be associated with more infection. The next aim was to investigate further the nature of the T cells reactive against the two 
major pathogens, P.aeruginosa and H.influenzae, in a sub-group of BR patients who were good responders to the antigens and in comparison 
to good-responding HV. There was a tendency for IFNγ, IL-2 and IL-17 to be reduced in BR patients compared to HV, suggesting greater 
antigen exposure, where memory T cells producing IL-2 convert to T cells secreting effector cytokines. Conversely, there was a tendency for 
IL-10 to be increased in BR for both antigens suggesting their conversion to a regulatory (Tr1) phenotype due to high and sustained antigen 
exposure at the mucosal surface. IL-4 responses showed a significant increase in BR against H.influenzae, similar to published work on COPD 
(32), but a tendency for the opposite for P.aeruginosa. This suggests a discrepancy in immune responses between BR and HV, and against 
the two pathogens, reflecting the fact that T cell response against H.influenzae was protective against disease. When pathogen-reactive T 
cells, based on CD69 and CD4 staining, were examined for further key phenotypic markers no differences were found between BR and HV. 
All reactive cells had high levels of CD49d, a lung homing receptor, but low levels of inflammatory homing receptors and the marker of 
senescence PD-1.   
The measurement of antibodies and T cells specific for P.aeruginosa and H.influenzae in patients with BR (29,30) and COPD (31,32) has 
previously revealed increased antibody responses associated with repeated infection, but decreased T cell responses, despite CD4+ T cell 
presence and oligoclonal TcR T cell expansion in the lungs (33,34), suggesting immune dysregulation such as T cell exhaustion. Thus, while 
immune responses may be protective, or a marker of infection by microbes, their dysregulation may be detrimental to the patient due to 
reduced protection from infection or through immunopathology as suggested in cystic fibrosis (35).  Studying responses in disease states is 
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important as this may reveal mechanisms of disease that are direct (via immunopathology) or indirect (via anti-microbial effects) that may 
provide therapeutic targets. Furthermore, studies of such blood-based immunodiagnostics may be useful for diagnosis and stratification of 
patients, and their responses to treatment (29), when microbiology or genomic analysis is not possible or reliable (young BR patients, no 
sputum, difficult to culture microbes, false negative). Baseline immunity related to contemporaneous microbiota may particularly be a useful 
way to identify a frequent exacerbator phenotype. With regard to an antibody marker of current colonization with P.aeruginosa, this data 
showed 92% specificity (ability to show true negatives) and 73% sensitivity (ability to show true positives) based on the HV mean + 2 sd.  This 
is similar to previous findings (29).  
The strengths of the study were the extensive nature of the immunological investigations carried out on patients, particularly those with BR, 
who were well characterised clinically and microbiologically. One weakness is that numbers of COPD patients producing sputum, and thus 
with positive cultures, was too low to allow a sufficiently powered analysis to be undertaken for COPD and so the study focussed on BR after 
the initial observations (Fig.1). Furthermore, it would have been useful to have longitudinal data of immune responses and microbiology, 
and this is the subject of a future study. Another weakness is that microbiological culture is not able to determine the complete microbial 
makeup in a sample if it contains fastidious unculturable bacteria. We are currently addressing this by carrying out genomic analysis of 
patient sputum samples as well as microbiological culture. Finally, the cytokine secretion data would have benefited from larger numbers, 
particularly for HV, and again this is the subject of ongoing work.  
Conclusion  
In conclusion, exposure to these lung pathogens generates antibody responses of magnitudes that are broadly proportional to the level of 
exposure and thus disease (exacerbation, reduced lung function), and may be useful markers of disease. T cell responses appear to be 
reduced in patients with increased infection rates, and are proportional to lung function and BSI for H.influenzae, suggesting that they may 
be protective against such a pathogen that is partially intracellular. The T cell responses in patients differ little in phenotype from HV, apart 
from possible subtle cytokine differences that are currently being examined further. The interaction between T cells and antibody-producing 
B cells, and how the two arms of the adaptive immune response interact and influence innate immunity, and ultimately impact on bacterial 
infection and disease, is likely to be complex and multifactorial. The data in this study suggests the use of antibodies for Pseudomonas-
inducing disease diagnosis, whilst T cells may indicate protective immunity against Haemophilus, suggesting a possible benefit of T cell-
inducing vaccines.   
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Table 1. Demographics of the subjects included in this study  
   Characteristics   BR n=119  COPD n= 
58  
HV n=28  
Sex (no.)  
Male/female )  
45/74  Not av.  Not av.  
Age (y)  65  ±   1.08          69   ±   1.23  54±3.01  
Exacerbations (per year)  4     ±  0.29  3    ±   0.38  Not app.  
Smoking history (pack 
years)  
8    ±  1.33  47  ±   4.08  Not av.  
FEV1 (% predicted)  68     ±  2.68  49  ±  2.70  113±2.83  
FVC (% predicted)  82     ± 2.48  77  ±   2.40  118± 2.7  
FEV1/FVC ratio   66    ±  1.52  50  ±  2.17  83±1.75  
Values are presented as means ± SEM, exacerbations represents the number per year. FEV1 represent forced expiratory volume in the first second and FVC, forced vital 
capacity. Not av, indicates the data are not available, whereas Not app means that the category was not applicable.   
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Table 2. Microorganisms isolated from the sputum of patients with BR and COPD.  
Microorganism Identified  Bronchiectasis 
patients (%)  
Chronic obstructive 
pulmonary  disease 
patients (%)  
NT. H.influenzae  63.8    31  
P. aeruginosa  56.3  12.0  
  
S. pneumoniae  44.5  17.2  
M. catarrhalis  
  
37.8  24.1  
A. fumigatus  22.6  3.4  
S. maltophilia  
  
15.9  3.4  
Candida. sp  14.4  6.9  
S aureus  30.3  1.7  
  
E.coli  
  20.1  5.2  
No pathogen isolated  
  2.5  17.2  
No sputum produced  6.8  43.7  
  
BR patients n=119; COPD patients n=58  
NT = non-typeable  
  
  
Table 3. Classification of patients based on sputum microbiological results  
0 
 
   
No pathogen isolated (NPI)    
1  Occasional   
  
>1 isolation in a year  
    
  
  
Chronic colonization is defined by the 
isolation of bacteria in sputum culture on 
2 or more occasions, 3 months apart, 
with 1 year  
2  Chronic previously  Chronic in preceding 5 years but not last 2 
years  
3  Chronic currently   
  
Current, and chronic in last 2 years prior 
to recruitment  
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Figure Legends  
Figure 1. Anti-bacterial antibody and T cells responses. Antibody levels against bacterial antigens were measured by ELISA: (a) IgG titres 
(1/value) against bacteria in BR, COPD and HV groups; (b) Antibody responses against bacteria were compared based on bacterial 
colonization. T cell responses against bacterial antigens were measured by IFNγ ELIspot: (a) IFNγ spot-forming cells per 106 PBMC against 
bacteria in BR, COPD and HV groups; (b) IFNγ spot-forming cells per 106 PBMC against bacteria were compared based on bacterial 
colonization. Anti-pseudomonas Ig subclasses and IgG isotypes in BR (e), COPD (f) and HV (g) subgroups. Mean value + SEM are given.  
*p<0.05, ***p<0.001. Mann-Whitney tests were performed.  
Figure 2. Lung function and exacerbation in BR. FEV1 % predicted is a measure of lung function. (a) FEV1 % predicted in BR patients 
grouped based on their bacterial colonization. (b) FEV1 % predicted in BR patients based on exacerbation in the last year, and in HV – 
healthy subjects. Mean values + SEM are given. Mann-Whitney tests were performed.  
Figure 3. Antibody and T cell responses in BR groups of different recent exacerbation history.  
Antibody levels against bacterial antigens were measured by ELISA to give IgG titres (1/value) in BR groups with <3 compared to >3 
exacerbations in the last 12 months against bacteria. T cell responses were measured by IFNγ ELIspot and expressed as spot-forming cells 
per 106 PBMC. (a,d) P.aeruginosa (b,e) M. catarrhalis (c,d) H.influenzae. Mean values + SEM are given. Mann-Whitney tests were 
performed.  
Fig.4 Cytokine responses in a subset of BR patients and HV. PBMC from BR and HV were stimulated with bacterial antigens P.aeruginosa 
(PSA) and H.influenzae (Hi), and supernatants were tested for the following cytokines: (a) IL-2, (b) IL-4, (c) IL-12, (d) IL-17, (e) IL-2, (f) IL-5, 
(g) IL-13, (h) IL-10. Mean values + SEM are given in pg/ml. Mann-Whitney tests were performed.  
Fig.5 Flow cytometry responses on a subset of BR patients and HV. Flow cytometry was performed on PBMC from BR and HV stimulated 
with bacterial antigens. (a) CD69 activation marker following stimulation with medium only, P.aeruginosa or H.influenzae. The % of CD4+ 
CD69+ activated T cells with phenotypic markers following stimulation with (b) P.aeruginosa, (c) anti-CD3 monoclonal antibody, (d) 
H.influenzae and (e) medium only. Mean % values + SEM are given. Mann-Whitney tests were performed.   
Fig.6 Lung function and BSI related to immune responses against H.influenzae in BR.  (a) T cell responses against H.influenzae measured 
by IFNγ ELIspot and expressed as spot-forming cells per 106 PBMC plotted against FEV1 % predicted. (b) T cells responses against 
H.influenzae plotted against BSI. (c) Antibody levels against H.influenzae were measured by ELISA to give IgG titres (1/value) in BR plotted 
against FEV1 % predicted. (d) Antibody responses against H.influenzae plotted against BSI. Spearman correlation was performed.   
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